DENVER, Dec. 14, 2017 /PRNewswire/ -- The following media statement is attributable to DaVita (NYSE: DVA).
We take full ownership and continue to embrace transparency and rigorous compliance.
DaVita is proud that its team discovered and self-disclosed these issues to the federal government in 2015 and 2016 and cooperated with the government in resolving them. As the DOJ said in its announcement, this settlement reflects the government's "willingness to work with providers who review their own practices and make appropriate self-disclosures." These amounts have been paid or previously accrued.
DaVita launched the country's first kidney care focused pharmacy over ten years ago and this innovative approach successfully addressed important unmet clinical needs of tens of thousands of kidney care patients at DaVita and elsewhere.
About DaVita Inc.
DaVita Inc., a Fortune 500® company, is the parent company of DaVita Kidney Care and DaVita Medical Group. DaVita Kidney Care is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end-stage renal disease. As of September 30, 2017, DaVita Kidney Care operated or provided administrative services at 2,470 outpatient dialysis centers located in the United States serving approximately 196,000 patients. The company also operated 230 outpatient dialysis centers located in 11 countries outside the United States. DaVita Medical Group manages and operates medical groups and affiliated physician networks in California, Colorado, Florida, Nevada, New Mexico, and Washington in its pursuit to deliver excellent-quality health care in a dignified and compassionate manner. DaVita Medical Group's teammates, employed clinicians and affiliated clinicians provided care for approximately 1.7 million patients. For more information, please visit DaVita.com/About.